CliniMACS® CD3/CD19 Product Line

The CliniMACS® CD3/CD19 Product Line consists of one reagent containing murine anti-CD3 and one reagent containing murine anti-CD19 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.

Each vial contains 7.5 mL sterile, non- pyrogenic solution.

The performance of the CliniMACS CD3/CD19 Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.

Please inquire about required CliniMACS System components and accessories.

Choose your product:

Related products for CliniMACS® CD3/CD19 Product Line

Specifications for CliniMACS® CD3/CD19 Product Line
Overview

The CliniMACS® CD3/CD19 Product Line consists of one reagent containing murine anti-CD3 and one reagent containing murine anti-CD19 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.

Each vial contains 7.5 mL sterile, non- pyrogenic solution.

The performance of the CliniMACS CD3/CD19 Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.

Please inquire about required CliniMACS System components and accessories.

Detailed product information
Applications

The CliniMACS CD3/CD19 Product Line was developed for the simultaneous depletion of unwanted T and B cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System. This approach keeps stem and progenitor cells untouched and leaves immune effector cells, such as NK cells and dendritic cells, in the cellular product.1,2

Disclaimer

The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.

CR/GMP products are for ex vivo cell processing only, and are not intended for human in vivo applications. CR/GMP products are designed, manufactured and tested under an ISO 13485 quality management system and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The manufacturing and testing of CR/GMP products of biological origin are in compliance with EP chapter 5.2.12 for “Raw materials of biological origin for the production of cell-based and gene therapy medicinal products”.

Product data and images for CliniMACS® CD3/CD19 Product Line
Figure 1

Flow cytometric analysis of simultaneous depletion of T and B cells from a buffy coat using the CliniMACS CD3/CD19 System.

T cell depletion
B cell depletion
Resources for CliniMACS® CD3/CD19 Product Line
Documents and Protocols
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CliniMACS® CD3/CD19 Product Line
Publications
  1. Barfield, R. C. et al. (2004) A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 6: 1-6
  2. Gordon, P. R. et al. (2002) A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant. 30: 69-74